(Q38003185)

26 August 2017

title

Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity (English)

1 reference

26 August 2017

0 references

0 references

Celia Oreja-Guevara

1

1 reference

26 August 2017

publication date

1 April 2012

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

26 August 2017

published in

1 reference

26 August 2017

volume

12

1 reference

26 August 2017

issue

4 Suppl

1 reference

26 August 2017

page(s)

3-8

1 reference

Rehabilitation in practice: Spasticity management

26 August 2017

cites work

1 reference

Prevalence and treatment of spasticity reported by multiple sclerosis patients

21 January 2018

1 reference

Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the '5E' study.

21 January 2018

1 reference

Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

Cannabis use in patients with multiple sclerosis

21 January 2018

1 reference

Combined cannabinoid therapy via an oromucosal spray

21 January 2018

1 reference

The medicinal use of cannabis in the UK: results of a nationwide survey.

21 January 2018

1 reference

Cannabinoids in the management of difficult to treat pain

21 January 2018

1 reference

Cannabinoid pharmacology: the first 66 years

21 January 2018

1 reference

Endocannabinoids and the regulation of their levels in health and disease

21 January 2018

1 reference

Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis

21 January 2018

1 reference

A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis.

21 January 2018

1 reference

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis.

21 January 2018

1 reference

Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis

21 January 2018

1 reference

A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols).

21 January 2018

1 reference

Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERN.12.11

1 reference

26 August 2017

1 reference